Comparative Pharmacology
Head-to-head clinical analysis: ADRENALIN versus SYMJEPI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADRENALIN versus SYMJEPI.
ADRENALIN vs SYMJEPI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct-acting sympathomimetic amine that acts on alpha- and beta-adrenergic receptors. Alpha-1 activation causes vasoconstriction, beta-1 activation increases heart rate and contractility, beta-2 activation causes bronchodilation.
Symjepi (epinephrine) is a direct-acting sympathomimetic amine that acts on alpha- and beta-adrenergic receptors. Alpha-adrenergic receptor activation leads to vasoconstriction, increased peripheral vascular resistance, and decreased mucosal edema. Beta-adrenergic receptor activation results in bronchodilation, positive inotropic and chronotropic cardiac effects, and relaxation of gastrointestinal smooth muscle.
1 mg (1 mL of 1:1000 solution) intramuscularly or subcutaneously every 5-20 minutes as needed; for cardiac arrest: 1 mg intravenously or intraosseously every 3-5 minutes.
0.3 mg intramuscular (IM) or subcutaneous (SC) injection into anterolateral aspect of thigh, repeat every 5-15 minutes as needed for anaphylaxis.
None Documented
None Documented
Approximately 2-3 minutes for the parent drug in plasma; clinical effects are short-lived due to rapid uptake and metabolism. In severe shock or hepatic impairment, half-life may be slightly prolonged.
The terminal elimination half-life of epinephrine is approximately 2-3 minutes when administered intravenously. This short half-life reflects rapid metabolic clearance and necessitates continuous infusion for sustained effect. After intramuscular injection, absorption is slower, but elimination half-life remains brief (about 2-5 minutes for the beta phase). The clinical context: Due to rapid clearance, the drug's effects wane quickly after discontinuation.
Primarily metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Renal excretion of metabolites (metanephrine, vanillylmandelic acid) and unchanged drug (<2% as unchanged). Biliary/fecal excretion is minimal (<5%).
Epinephrine is rapidly metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Metabolites, primarily metanephrine and vanillylmandelic acid (VMA), are excreted in urine. Less than 5% of administered dose is excreted unchanged in urine. Biliary/fecal elimination is negligible.
Category C
Category C
Adrenergic Agonist
Adrenergic Agonist